Evidence map›Paper›PMID 34079523›Full record

ReviewFrontiers in endocrinology2021

Human Pluripotent Stem Cells Go Diabetic: A Glimpse on Monogenic Variants.

Sandra Heller, Michael Karl Melzer, Ninel Azoitei, Cécile Julier, Alexander Kleger

Abstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Experimental models in diabetes research.Laboratory animal research · 2026
    Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sandra HellerDepartment of Internal Medicine I, Ulm University Hospital, Ulm, Germany.
Michael Karl MelzerDepartment of Internal Medicine I, Ulm University Hospital, Ulm, Germany.
Ninel AzoiteiDepartment of Internal Medicine I, Ulm University Hospital, Ulm, Germany.
Cécile JulierUniversité de Paris, Institut Cochin, INSERM U1016, CNRS UMR-8104, Paris, France.
Alexander KlegerDepartment of Internal Medicine I, Ulm University Hospital, Ulm, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes, as one of the major diseases in industrial countries, affects over 350 million people worldwide. Type 1 (T1D) and type 2 diabetes (T2D) are the most common forms with both types having invariable genetic influence. It is accepted that a subset of all diabetes patients, generally estimated to account for 1-2% of all diabetic cases, is attributed to mutations in single genes. As only a subset of these genes has been identified and fully characterized, there is a dramatic need to understand the pathophysiological impact of genetic determinants on

Indexed as

MutationAnimalsCell DifferentiationCell LineageCRISPR-Cas SystemsDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Embryonic Stem CellsEpigenesis, GeneticGene EditingGenetic VariationHeterozygoteHumansInsulinInsulin-Secreting CellsMiceInsulindiabetesMaturity Onset of Diabetes in the Youngmonogenic variantspluripotent stem cellstype 1 diabetestype 2 diabetes

Identifiers

PMID34079523
PMCPMC8166226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.